Monday, March 23, 2015
CLEVELAND – University Hospitals Case Medical Center has been selected as one of only 50 hospitals in the United States to participate in the LEVO-CTS trial, a landmark national study in cardiac surgery.
The LEVO-CTS trial aims to study the potential benefits of levosimendan in high-risk cardiac surgery patients, and has the potential to transform treatment and outcomes for these patients. University Hospitals Case Medical Center’s trial, run by Soon Park, MD, Division Chief of Cardiac Surgery, UH Case Medical Center, and Co-Director, Harrington Heart and Vascular Institute, is one of the LEVO-CTS trial’s highest enrolling centers.
“University Hospitals Case Medical Center is one of the top cardiac surgery hospitals in the United States, with a high volume of patients and significant clinical research experience,” said John Kelley, CEO of Tenax Therapeutics, the LEVO-CTS trial sponsor. “Dr. Park and Case Medical Center have a reputation that speaks for itself, and we are very excited about their contribution to the LEVO-CTS trial.”